N/A
Completed N=842
Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: the TESTsmART Trial AIM 1
Malaria · Febrile Illness
Source: ClinicalTrials.gov NCT03810014 ↗
Enrolled (actual)
842
Serious AEs
0.0%
Results posted
Nov 2020
Primary outcomePrimary: Number of Participants That Purchase an mRDT (Malaria Rapid Diagnostic Test) — 205; 195; 207; 211 Participants — p=0.01
Summary
The TESTsmART Trial consists of two main aims. The overall goal of the two aims is to investigate the impact of malaria rapid diagnostic test (mRDT) subsidies and conditional artemisinin combination therapy (ACT) subsidies on the testing and treatment behavior of participants seeking care for their febrile illness in the private retail sector. Conditional ACT subsidies are discounts on quality-assured ACTs which are linked to the results of a malaria rapid diagnostic test administered at the retail outlet; only participants with a positive test will have access to an additional discount on a quality-assured ACT.
The main objective of Aim 1 of this study is to identify a combination of conditional ACT and RDT subsidies that maximizes the proportion of participants that choose to have a malaria diagnostic test before taking a drug. The investigators will test two levels of conditional ACT subsidy (100% subsidy versus ~67% subsidy) and two levels of RDT subsidy (0% subsidy and 50% subsidy) in a factorial designed experiment. Because dose size and therefore the price of an ACT course are dependent upon patient age, the ACT subsidy amount will also be scaled with patient age. These subsidy levels were chosen to keep the estimated program cost of the combined subsidy within $0.30-0.60 USD per person (assuming 100% testing uptake and between 20-40% of participants having a positive RDT). These estimates represent an upper bound since testing is unlikely to reach 100%. Current subsidy levels for ACT costs the program between 1.30-2.50 USD per treatment, with more than a third of that investment spent on individuals without malaria.
Individuals presenting to a retail outlet for a treatment of a fever or suspected malaria illness will be randomized to one of the four groups in equal proportions. A total of 840 participants will be enrolled (210 per arm). Their choices concerning uptake of testing and drug purchase will be recorded. The main outcome will be the proportion of participants that choose to take a test. Secondary outcomes include the proportion of participants who adhered to the results of the RDT among those who were tested (used ACT when positive and did not use an ACT when negative or without a test). The results of this study will be used to inform the subsidy levels in the intervention for Aim 2 of this trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants That Purchase an mRDT (Malaria Rapid Diagnostic Test) |
205; 195; 207; 211 | 0.01 sig |
| SECONDARY Number of Participants With a Positive mRDT That Purchased an ACT (Artemisinin-based Combination Therapy) |
47; 39; 24; 40 | — |
| SECONDARY Number of Participants With a Negative mRDT That Did Not Purchase an ACT |
144; 132; 166; 155 | — |
| SECONDARY Number of Participants That Did Not Purchase an mRDT and Did Not Purchase an ACT |
4; 5; 3; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Participants with fever or history of fever or malaria like illness
- Individual with malaria-like illness must be present at recruitment
- 1 year of age or older
Exclusion Criteria
- Any individual with signs of severe illness requiring immediate referral
- Individuals who have taken an antimalarial in the last seven days, including for the current illness
- Individuals who already have a prescription from a facility or medical provider
- Pregnant women will be enrolled and offered an mRDT, but will be advised to seek treatment through a health care provider.
Data sourced from ClinicalTrials.gov (NCT03810014). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.